(RTTNews) - Alumis Inc. (ALMS) announced positive 52-week data from the open-label extension (OLE) of its Phase 2 STRIDE clinical trial evaluating ESK-001 in patients with moderate-to-severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback